Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Clopidogrel
Drug ID BADD_D00504
Description Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Indications and Usage Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Marketing Status approved
ATC Code B01AC04
DrugBank ID DB00758
KEGG ID D07729; D10823; D10824
MeSH ID D000077144
PubChem ID 60606
TTD Drug ID D0N0TZ
NDC Product Code 42543-714; 50090-4918; 52605-083; 16729-218; 0024-1171; 68788-8190; 72578-012; 65977-0037; 52605-082; 63187-362; 63629-4728; 70518-0400; 33342-060; 42543-713; 65162-414; 0093-7314; 16729-219; 61919-007; 67296-1840; 50090-2598; 50090-5781; 0024-1332; 61919-737; 70771-1062; 16714-052; 68071-2813; 68071-4138; 71335-0581
UNII A74586SNO7
Synonyms Clopidogrel | SC 25989C | SC 25990C | SR 25989 | Clopidogrel-Mepha | Clopidogrel Mepha | Clopidogrel Sandoz | Iscover | Clopidogrel Napadisilate | Clopidogrel Hydrochloride | PCR 4099 | PCR-4099 | Clopidogrel Besylate | Clopidogrel Besilate | Clopidogrel, (+)(S)-isomer | Plavix | Clopidogrel Bisulfate
Chemical Information
Molecular Formula C16H16ClNO2S
CAS Registry Number 113665-84-2
SMILES COC(=O)C(C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Mediastinal haemorrhage24.07.01.075; 22.09.03.0080.000032%
Cell death14.11.02.005; 08.03.03.0030.000021%Not Available
Peripheral artery occlusion24.04.03.0220.000021%Not Available
Subacute cutaneous lupus erythematosus10.04.03.012; 23.03.02.020; 15.06.02.0120.000021%Not Available
Sopor19.02.04.002; 17.02.04.0210.000139%Not Available
Haemorrhagic cyst24.07.01.069; 16.02.02.013; 08.03.05.0080.000021%Not Available
Intracranial haematoma24.07.04.027; 17.08.01.0510.000021%Not Available
Coronary artery perforation12.02.01.022; 02.02.01.0140.000053%Not Available
Haemorrhagic ascites24.07.02.032; 09.01.05.007; 07.07.02.0030.000064%Not Available
Gastrointestinal erosion07.04.04.0090.000053%Not Available
Embolic cerebral infarction24.01.04.009; 17.08.01.0290.000021%Not Available
Diffuse alveolar damage22.01.01.0190.000032%Not Available
Arterial haemorrhage24.07.01.0630.000075%Not Available
Cerebellar haematoma24.07.04.022; 17.08.01.0450.000021%Not Available
Communication disorder19.19.01.0080.000021%Not Available
Deformity08.01.03.0220.000107%Not Available
Small intestinal stenosis07.13.06.0080.000021%
Bladder tamponade24.07.01.064; 20.02.02.0240.000021%Not Available
Basilar artery thrombosis24.01.04.014; 17.08.01.0430.000053%Not Available
Renal embolism20.01.07.014; 24.01.11.0030.000021%Not Available
Breast haematoma24.07.03.020; 21.05.05.0130.000021%Not Available
Eyelid haematoma23.06.07.007; 12.01.04.025; 06.07.05.002; 24.07.05.0130.000032%Not Available
Gastric fistula12.02.03.018; 07.11.05.0110.000021%
Basal ganglia haemorrhage17.08.01.039; 24.07.04.0210.000053%Not Available
Carotid arteriosclerosis17.08.02.015; 24.04.06.0310.000021%Not Available
Cerebral microhaemorrhage24.07.04.025; 17.08.02.0190.000032%Not Available
Abdominal wall haematoma24.07.02.039; 07.16.05.0050.000160%Not Available
Apparent death08.01.03.0620.000021%Not Available
Dieulafoy's vascular malformation24.03.03.025; 07.15.04.0020.000032%Not Available
Respiratory fatigue22.02.01.0420.000021%Not Available
The 25th Page    First    Pre   25 26 27    Next   Last    Total 27 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene